Seer Urges Shareholders to Reject Radoff-JEC Group’s Board Nominees Ahead of Annual Meeting — Seer, Inc.

Event summary

Seer’s board urges shareholders to vote 'FOR' its seven director nominees on the BLUE proxy card ahead of the July 28, 2026 annual meeting.
The board highlights the qualifications and independence of its nominees, including Omid Farokhzad, Robert Langer, and Deep Nishar.
Seer’s board owns 17% of the company’s outstanding shares as of May 11, 2026.
Bradley Radoff and Michael Torok are pushing for an early sale of Seer, nominating directors without proteomics or life sciences tools experience.

The big picture

Seer is navigating a proxy fight that pits its board’s long-term growth strategy against Radoff-JEC Group’s push for an early sale. The outcome will determine the direction of the company in the proteomics market, where Seer aims to maintain its leadership position through deep, unbiased proteomics and population-scale studies.

What we're watching

Governance Dynamics: Whether Seer’s board can maintain control and execute its long-term growth strategy amid the proxy fight.
Strategic Execution: How the outcome of the vote will impact Seer’s commercial adoption and market leadership in proteomics.
Shareholder Value: The pace at which Seer can deliver on its commitments to operational discipline, product innovation, and shareholder value creation.